Mutant RAS:p-RAF complexes phosphorylate MAP2Ks

Stable Identifier
R-HSA-6802926
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

MAP2K proteins are phosphorylated downstream of oncogenic RAS mutants; somewhat surprisingly, however, steady state levels of phospho-MAP2K and phospho-MAPKs are not always elevated in cancer cells (reviewed in Ramos, 2008; Neuzillet et al, 2014; Stephen et al, 2014).

Literature References
PubMed ID Title Journal Year
24121058 MEK in cancer and cancer therapy

Neuzillet, C, Tijeras-Raballand, A, de Mestier, L, Cros, J, Faivre, S, Raymond, E

Pharmacol. Ther. 2014
18562239 The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells

Ramos, JW

Int. J. Biochem. Cell Biol. 2008
24651010 Dragging ras back in the ring

Stephen, AG, Esposito, D, Bagni, RK, McCormick, F

Cancer Cell 2014
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
protein serine/threonine kinase activity of mutant RAS:GTP:p-RAF:MAP2Ks:MAPKs:scaffold proteins [plasma membrane]
Physical Entity
Activity
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created